What's changing in Medicare's open enrollment this year?

AdobeIt’sthemiddleofOctober—thetimeofyearthat’sfilledwithpumpkinspicelattes,jumbo-sizedbagsofHallowe 6:09FILE-AnApplelogoadornsthefacadeofthedowntownBrooklynApplestoreonMarch14,2020,inNewYork.Applebeca




explore

author：focus    Page View：1
Alexis Borisy
Venture capitalist Alexis Borisy Vanessa Leroy for STAT

EQRx is done, sold for its cash.

The once-buzzy but now dormant biotech company is being acquired by Revolution Medicines, a developer of cancer drugs, the companies announced Tuesday.

advertisement

The all-stock deal is essentially a balance-sheet transfer of $1 billion in cash from EQRx to Revolution. What was left of EQRx’s drug pipeline is being shelved.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In
Previous article： Infant mortality in U.S. rose last year for first time in decades: CDC
Next article： Hollywood unions extend contract negotiations for actors